112 related articles for article (PubMed ID: 19437374)
21. Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Massenkeil G; Nagy M; Le Coutre P; Heine F; Rosen O; Dörken B; Arnold R
Hematol J; 2004; 5(5):395-402. PubMed ID: 15448665
[TBL] [Abstract][Full Text] [Related]
22. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
Kasper C; Sayer HG; Mügge LO; Schilling K; Scholl S; Issa MC; Höffken K
Bone Marrow Transplant; 2004 Jan; 33(1):65-9. PubMed ID: 14704658
[TBL] [Abstract][Full Text] [Related]
23. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation.
Menillo SA; Goldberg SL; McKiernan P; Pecora AL
Bone Marrow Transplant; 2001 Oct; 28(8):807-8. PubMed ID: 11781637
[No Abstract] [Full Text] [Related]
24. Effect of splenectomy on pancytopenia after a peripheral blood stem cell transplantation.
Ding J; Bao W; Wang J; Zhao G; Chen J; Song H
Cell Transplant; 2011; 20(7):1109-15. PubMed ID: 21092413
[TBL] [Abstract][Full Text] [Related]
25. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
26. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
27. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
28. Acute graft-versus-host disease, invasive aspergillosis and Clostridium difficile colitis after peripheral blood stem cell transplantation: A complex network of causalities and a challenge for prevention.
Khanafer N; Neuraz A; Bénet T; Cour M; Persat F; Labussière H; Argaud L; Michallet M; Vanhems P
Anaerobe; 2015 Jun; 33():98-100. PubMed ID: 25749258
[TBL] [Abstract][Full Text] [Related]
29. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease.
Calzavara Pinton P; Porta F; Izzi T; Venturini M; Capezzera R; Zane C; Notarangelo LD
Haematologica; 2003 Oct; 88(10):1169-75. PubMed ID: 14555314
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
Solomon SR; Nakamura R; Read EJ; Leitman SF; Carter C; Childs R; Dunbar CE; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
[TBL] [Abstract][Full Text] [Related]
31. [Prophylactic effect of CsA, MTX, MMF combined with ATG on GVHD in patients underwent unrelated peripheral blood hematopoietic stem cell transplantation].
Li XH; Gao CJ; Da WM; Yu L; Wu XX; Li HH; Ma J; Cao YB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):458-62. PubMed ID: 20416188
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
[TBL] [Abstract][Full Text] [Related]
33. Combining PUVA therapy with systemic immunosuppression to treat progressive diffuse morphoea.
Rose RF; Goodfield MJ
Clin Exp Dermatol; 2005 May; 30(3):226-8. PubMed ID: 15807674
[TBL] [Abstract][Full Text] [Related]
34. Chronic cutaneous sclerodermoid graft-versus-host disease: evaluation by 20-MHz sonography.
Gottlöber P; Leiter U; Friedrich W; Bunjes D; Schulz A; Kerscher M; Peter RU
J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):402-7. PubMed ID: 12834449
[TBL] [Abstract][Full Text] [Related]
35. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
37. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung.
Bolaños-Meade J; Ioffe O; Hey JC; Vogelsang GB; Akpek G
Am J Hematol; 2005 Jun; 79(2):132-5. PubMed ID: 15929116
[TBL] [Abstract][Full Text] [Related]
38. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
[TBL] [Abstract][Full Text] [Related]
39. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
[TBL] [Abstract][Full Text] [Related]
40. Sclerodermatous changes of chronic graft-versus-host-disease treated with puva.
Woscoff A; Ruíz Lascano A; De Pablo AB; Robinson A
Int J Dermatol; 1996 Sep; 35(9):656-8. PubMed ID: 8876297
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
